STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: MDA 19

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

- Controlled X
- Not Controlled □

under the schedules of the *Controlled Drugs and Substances Act* (CDSA) for the following reason(s):

- The substance shows cannabinoid receptor agonist activity and must be included under item 1 of Schedule II to the CDSA.

Prepared by: __________________________________________________________________________ Date: __________

Zack Li

Verified by: __________________________________________________________________________ Date: __________

Mark Kozlowski

Approved by: __________________________________________________________________________ Date: __________

DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: “third party information removed as per agreement with applicant”
Drug: MDA 19

Drug Name Status: MDA 19 is the common name.

Chemical Name: N'<(3Z)-1-Hexyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide

Other Names: MDA19

Chemical structure:

```
O
\   \n\   \nN=\   \n\   \nC=C\   \n\   \n```

Molecular Formula: C_{21}H_{23}N_{3}O_{2}

Pharmacological class / Application: Synthetic cannabinoid

CAS-RN: 1048973-47-2

International status:

US: MDA 19 is not listed specifically in the Schedules to the US Controlled Substances Act and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.

Canadian Status: MDA 19 is not listed in the schedules to the CDSA. The substance is a synthetic cannabinoid and has shown to bind to the CB1 and CB2 cannabinoid receptors (K_i = 162.4 ± 7.6 nM and K_i = 43.3 ± 10.3), and display potent cannabinoid agonist activity in in vivo studies\(^1\). Cannabinoid receptor agonists have been included under item 1 of Schedule II to the CDSA under the heading “Cannabis, its preparations, derivatives and similar synthetic preparations”. Given that MDA 19 demonstrates cannabinoid receptor agonist activity, it must be included under item 1 of Schedule II to the CDSA.

Recommendation: MDA 19 is included in item 1 of Schedule II to the CDSA and is a controlled substance.

Date: May 24th, 2012.